2 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
The following table presents the total compensation for each person who served as a non-executive member of our board of directors and received compensation for such service during the fiscal year ended December 31, 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or awards to, or pay any other compensation to any of the members of our board of directors in 2023. We reimburse members of our board of directors for reasonable travel expenses. Dr. Scots-Knight, our Chief Executive Officer, did not receive any compensation for her service as a member of our board of directors in 2023. Dr. Scots-Knight’s compensation for service as an employee for fiscal years 2023 and 2022 is presented in “Executive Compensation—2023 Summary Compensation Table .”
Fees Earned or Paid in Cash (1) | Stock Awards (2) | Option Awards (2) | Total | |||||||||||||
Name | ($) | ($) | ($) | ($) | ||||||||||||
Dr. Jeremy Bender | — | 58,669 | 46,412 | 105,082 | ||||||||||||
Dr. Anders Ekblom | — | 74,894 | 46,412 | 121,306 | ||||||||||||
Dr. Pierre Jacquet | — | 55,771 | 46,412 | 102,184 | ||||||||||||
Dr. Annalisa Jenkins | — | 54,550 | 46,412 | 100,963 | ||||||||||||
Dr. Deepika R. Pakianathan | 67,349 | — | 46,412 | 113,761 | ||||||||||||
Justin Roberts (3) | — | — | — | — | ||||||||||||
Dr. Daniel Shames | — | 51,336 | 46,412 | 97,748 | ||||||||||||
Marc Yoskowitz | — | 48,076 | 46,412 | 94,488 | ||||||||||||
Michael S. Wyzga | — | 110,384 | 46,412 | 156,797 |
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
Each named executive officer’s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our board of directors taking into account each individual’s role, responsibilities, skills, and experience. Base salaries are typically reviewed annually, with any increases normally taking effect from the first day of January. When awarding salary increases, the Remuneration Committee will consider the level of increase proposed for the wider workforce, as well as employee pay conditions more broadly in comparison to our peer group companies and inflation. Where there has been a change in the role, or if the individual is new to the role, increases could be higher. The base salary of each named executive officer is noted below:
2023 Annual Base Salary | 2022 Annual Base Salary | |||||||
Name | ($) | ($) | ||||||
Dr. Denise Scots-Knight (1) | 565,107 | 506,809 | ||||||
Charles Sermon (1) | 415,651 | 372,772 | ||||||
Christine Fox (1) | 378,120 | 332,833 |
- Prev
- 1
- Next